This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chandler, W. L. Articles by Stratton, J. R. Search for Related Content PubMed PubMed Citation Articles by Chandler, W. L. Articles by Stratton, J. R.

(Circulation. 1995;92:2984-2994.)
© 1995 American Heart Association, Inc.

Articles

The Circulatory Regulation of TPA and UPA Secretion, Clearance, and Inhibition During Exercise and During the Infusion of Isoproterenol and Phenylephrine

Wayne L. Chandler, MD; Wayne C. Levy, MD; John R. Stratton, MD

From the Department of Laboratory Medicine (W.L.C.) and the Division of Cardiology, Department of Medicine (W.C.L., J.R.S.), University of Washington and Seattle VA Medical Center.

Correspondence to Wayne L. Chandler, MD, Department of Laboratory Medicine, SB-10, University of Washington, Seattle, WA 98195.

Background Exercise to exhaustion and infusions of isoproterenol and phenylephrine were used to study interactions between plasminogen activator regulation and the control of regional blood flow in 10 healthy males.

Methods and Results Experimental measurements of cardiac output, heart rate, tissue plasminogen activator (TPA), urokinase plasminogen activator (UPA), plasminogen activator inhibitor (PAI-1), C1-inhibitor, and TPA/C1-inhibitor complex during the infusions and exercise were used to develop a comprehensive fluid-phase model of the circulatory regulation of fibrinolysis. - and ß-adrenergic agonists increased TPA and UPA in plasma by different mechanisms: Phenylephrine decreased hepatic blood flow and thus clearance while isoproterenol stimulated increased secretion of TPA and UPA. Exercise to exhaustion increased TPA and UPA through a combination of increased secretion and decreased clearance. The time course of UPA and TPA release were similar, but the magnitude of their secretion responses differed. In vivo, C1-inhibitor bound to TPA at a rate of 553 mol^-1 · s^-1. C1-inhibitor contributed equally with PAI-1 to TPA inhibition when active PAI-1 levels were low (20 to 50 pmol/L) but was less important when active PAI-1 levels were high.

Conclusions We conclude that secretion, inhibition, clearance, and regional blood flow effects must all be taken into account when evaluating changes in plasminogen activator levels.

Key Words: plasminogen activators • exercise

This article has been cited by other articles:

				C. Giannarelli, A. Virdis, F. De Negri, E. Duranti, A. Magagna, L. Ghiadoni, A. Salvetti, and S. Taddei Tissue-Type Plasminogen Activator Release in Healthy Subjects and Hypertensive Patients: Relationship With {beta}-Adrenergic Receptors and the Nitric Oxide Pathway Hypertension, August 1, 2008; 52(2): 314 - 321. [Abstract] [Full Text] [PDF]

				L. Lovrecic, S. Ristic, N. Starcevic-Cizmarevic, B. Brajenovic-Milic, Sasa Sega Jazbec, J. Sepcic, M. Kapovic, and B. Peterlin PAI and TPA gene polymorphisms in multiple sclerosis Multiple Sclerosis, March 1, 2008; 14(2): 243 - 247. [Abstract] [PDF]

				J.-A. Bjorkman, S. Jern, and C. Jern Cardiac Sympathetic Nerve Stimulation Triggers Coronary t-PA Release Arterioscler. Thromb. Vasc. Biol., June 1, 2003; 23(6): 1091 - 1097. [Abstract] [Full Text] [PDF]

				R. von Kanel, J. E. Dimsdale, K. A. Adler, E. Dillon, C. J. Perez, and P. J. Mills Effects of nonspecific beta -adrenergic stimulation and blockade on blood coagulation in hypertension J Appl Physiol, April 1, 2003; 94(4): 1455 - 1459. [Abstract] [Full Text] [PDF]

				M. T. Sartori, G. Saggiorato, L. Spiezia, C. Varvarikis, G. Carraro, G. M. Patrassi, and A. Girolami Influence of the Alu-Repeat I/D Polymorphism in t-PA Gene Intron 8 on the Stimulated t-PA Release After Venous Occlusion Clinical and Applied Thrombosis/Hemostasis, January 1, 2003; 9(1): 63 - 69. [Abstract] [PDF]

				D. Huber, E. M. Cramer, J. E. Kaufmann, P. Meda, J.-M. Masse, E. K. O. Kruithof, and U. M. Vischer Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo Blood, May 15, 2002; 99(10): 3637 - 3645. [Abstract] [Full Text] [PDF]

				W. L. Chandler, M. L. Jascur, and P. J. Henderson Measurement of Different Forms of Tissue Plasminogen Activator in Plasma Clin. Chem., January 1, 2000; 46(1): 38 - 46. [Abstract] [Full Text] [PDF]

				C. Rosnoblet, U. M. Vischer, R. D. Gerard, J.-C. Irminger, P. A. Halban, and E. K. O. Kruithof Storage of Tissue-Type Plasminogen Activator in Weibel-Palade Bodies of Human Endothelial Cells Arterioscler. Thromb. Vasc. Biol., July 1, 1999; 19(7): 1796 - 1803. [Abstract] [Full Text] [PDF]

				C. Jern, P. Ladenvall, U. Wall, and S. Jern Gene Polymorphism of t-PA is Associated With Forearm Vascular Release Rate of t-PA Arterioscler. Thromb. Vasc. Biol., February 1, 1999; 19(2): 454 - 459. [Abstract] [Full Text] [PDF]

				C. M. Stein, N. Brown, D. E. Vaughan, C. C. Lang, and A. J. J. Wood Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature J. Am. Coll. Cardiol., July 1, 1998; 32(1): 117 - 122. [Abstract] [Full Text] [PDF]